Mepro is committed to serve humanity by helping eradicate diseases and helping the less fortunate by providing healthcare to everyone. With the current ongoing global pandemic, COVID-19, Mepro has globally collaborated and has provided for emergency stock-pile support therapies for coronavirus treatments for deeply affected countries in Latin America. Mepro stands for and is determined to provide access to its efficacious products for meaningful and progressive endeavours for an overall societal well-being.
Mepro Pharmaceuticals Pvt. Ltd.
A globally competitive organisation formulating a wide range
of medicines and exports to more than 40 countries
State-of-the-art manufacturing facilities spread across 3 different cities
Technology and precision-driven processes ensuring adherence to quality
Tailor-made, end-to-end solutions to meet custom requirements
Implementing an ever-evolving regulatory framework through application of QbD principles
Developing novel drug delivery systems to launch sterile formulations, complex generics, and orphan drugs
Our employee-first approach ensures empowered employees translating our vision into action at the front line
Designed to meet stringent regulatory authorities like EU, UK, UNICEF etc., this unit produces tablets, capsules, creams, ointments and gels. It caters to the regulated and semi-regulated markets in 40 countries across the world.Learn More
Our latest plant in Baroda is built with state-of-the-art technology to meet the ever-growing demands of the US, Europe, Brazil, Canada, and Australia-NZ. With this plant, we have taken a leap into manufacturing complex generics in the sterile space including lyophilised products and prefilled syringes.Learn More
Based at Uttarakhand, this unit caters to the emerging domestic market. It houses 2 blocks within itself: the first one produces tablets, capsules, creams, and ointments, while the second one produces Dry Powder Carbapenem Injectables.Learn More
State-of-the-art Manufacturing Facilities
As the name suggests, ‘Neglected’ Tropical Diseases like Soil Transmitted Helminths (STH) or simply put ‘Intestinal worms’ are indeed vastly neglected in Low & Middle Income countries of Africa and Asia. This is particularly disconcerting when an estimated 266 million preschool children are at the risk of STH infections, which, if left untreated can cause abdominal pain/distention, stunted growth, anemia, impaired cognitive development, and compromised nutrition. In a bid to eradicate this, Mepro has tied up with a global non-profit organisation for manufacturing and supply of a drug in its treatment therapy. Through its partners vast distribution network, approximately 42 million children in the age bracket of 12-59 months are being reached out to and treated each year.
Mepro has been a partner of choice to quite a few United Nations organizations since more than a decade. It’s through one of these organizations, Mepro is supporting healthcare needs of almost 5.6 million Palestinian refugees now residing across West bank, Gaza, Lebanon, Jordan and Syria. This has been stitched across 10 products in acute as well as chronic segments under a long-term supply and sustenance agreement.
Built in mind keeping the highest global healthcare standards, Mepro’s newly constructed Unit III has received its EU GMP Approval in the first year of its operation.
Captured 35% market share for 3 products in the UK in its 1st year of inception.
Mepro has received approval and launched 2 ‘first to file’ Complex Haemorrhoidal Products in Australia and New Zealand with no Generic competition as yet.
Mepro has been funded a Grant from USAID for development and commercialization for a drug in the neglected tropical diseases segment.
A testament to its strong R&D, Mepro has scheduled WHO PQ filing for a product making it’s first Generic entry into the World Health Organisation’s PQ Programme.
Further adding to its global presence Mepro recently commenced operations in Malaysia, HongKong and Chile across CVS and Derma range.